A South Korean pharmaceutical company has sparked massive investor enthusiasm and propelled its chairman into billionaire status after announcing a promising new weight-loss pill. The company, Sam Chun Dang Pharm (SCD), was founded in 1943 and has been developing innovative treatments for various health conditions over the years.
The latest development is S-Pass, a novel drug delivery system that transforms injectable medicines into easy-to-take pills. This breakthrough technology has caught the attention of investors, with shares skyrocketing by more than 75% this month alone. Yoon Dae-in, the chairman of SCD, now holds an estimated net worth of $2.1 billion, making him a prominent figure in South Korea's biotech and pharma billionaire club.
The weight-loss pill has been jointly developed with Daiichi Sankyo and is expected to be commercialized in Japan. The company has also received recognition from Seoul-based investment bank Korea Investment & Securities, which selected it as a "recommended stock of the week" due to its potential for clinical success.
In addition to S-Pass, SCD is developing another innovative treatment using microspheres to release drugs slowly over several months. This technology is being used to treat prostate cancer, and the company has signed an agreement with Takeda that could be worth up to $2 billion.
SCD's financial performance has also been impressive, with revenue rising 6.3% year-over-year to $113 million in the first nine months of 2025. Net income increased by 76% during the same period, further solidifying the company's position as a major player in the pharmaceutical industry.
With its commitment to innovation and cutting-edge technology, SCD is well-positioned for continued success in the market. As Yoon Dae-in continues to lead the company, it will be exciting to see how S-Pass and other developments shape the future of healthcare treatment and patient care.
The latest development is S-Pass, a novel drug delivery system that transforms injectable medicines into easy-to-take pills. This breakthrough technology has caught the attention of investors, with shares skyrocketing by more than 75% this month alone. Yoon Dae-in, the chairman of SCD, now holds an estimated net worth of $2.1 billion, making him a prominent figure in South Korea's biotech and pharma billionaire club.
The weight-loss pill has been jointly developed with Daiichi Sankyo and is expected to be commercialized in Japan. The company has also received recognition from Seoul-based investment bank Korea Investment & Securities, which selected it as a "recommended stock of the week" due to its potential for clinical success.
In addition to S-Pass, SCD is developing another innovative treatment using microspheres to release drugs slowly over several months. This technology is being used to treat prostate cancer, and the company has signed an agreement with Takeda that could be worth up to $2 billion.
SCD's financial performance has also been impressive, with revenue rising 6.3% year-over-year to $113 million in the first nine months of 2025. Net income increased by 76% during the same period, further solidifying the company's position as a major player in the pharmaceutical industry.
With its commitment to innovation and cutting-edge technology, SCD is well-positioned for continued success in the market. As Yoon Dae-in continues to lead the company, it will be exciting to see how S-Pass and other developments shape the future of healthcare treatment and patient care.
I mean, who wouldn't want to make money off people trying to lose weight? 
But at the same time, isn't it kinda weird that we're relying on more and more pharmaceutical companies to solve our health issues? Like, shouldn't we be focusing on lifestyle changes or something? 
And what's up with this whole "recommended stock of the week" thing? Is Korea Investment & Securities just trying to make a quick buck off unsuspecting investors? 
I mean, a weight loss pill that's actually gonna work? It's like something outta a sci-fi movie! 
And the fact that SCD's shares are skyrocketing is insane - like, who wouldn't wanna invest in a company with this kind of tech behind it? 
I'm also loving the fact that Yoon Dae-in is now a billionaire, he must be living his best life! 
And $2 billion is just crazy talk for an agreement with Takeda... what's next, a cure for cancer or something? 
That's amazing news too. The future of healthcare just got brighter. SCD is killing it with these innovations! 
I'm also loving the fact that Yoon Dae-in is a total boss, leading his company to success. He's an inspiration! 
Let's keep rooting for him and SCD 
I'm kinda worried about this weight-loss pill thingy... Like, what's next? Are we gonna start pushing these pills on everyone just because they're 'promising'? What's the catch? Is it really that safe? We need to make sure that big pharma companies like SCD are prioritizing patient safety over profits. 
I'm all for innovation, but let's not rush into this without doing our due diligence. We gotta keep an eye on these giants and make sure they're playing by the rules. 
The big question is can they actually deliver on those promises? I mean, these breakthroughs sound amazing, but history has shown us that big claims rarely live up to expectations 
. Still, it's awesome to see innovation like S-Pass getting so much attention - maybe this is the start of a new era in pharma 
. And Yoon Dae-in's rags-to-riches story is pretty inspiring too 
. The real test will be when they're faced with the scrutiny of actual clinical trials and regulatory hurdles 
. Fingers crossed they can make it all work out without any major setbacks 
. I mean, who wouldn't want to work for Yoon Dae-in with his innovative ideas and track record of success? It's like he's got a PhD in making money 
. I'm rooting for this company to continue pushing the boundaries of healthcare and making lives better 
. The company's got some big shoes to fill now with their stocks skyrocketing, but I'm excited to see how they continue to grow and make a positive impact on people's lives 
.
? but seriously, it's awesome that sam chung dang pharm is innovating and taking risks 
they deserve all the recognition from investment banks 
.
.
I mean, he's got his S-Pass weight loss pill, which is gonna be HUGE in Japan 
, and now he's raking it in 
. I'm rooting for him! 
and its amazing to think that there's a new hope on the horizon 
. did anyone know about daiichi sankyo's involvement in this project? they're always doing something innovative 
and it's awesome to see sam chun dang pharm partnering with them 
but seriusly tho sam chun dang pharm is on da rise & its gonna be interesting 2 c how their innovations impact healthcare. btw yoon dae-in is livin his best life rn with dat billionaire status 
I'm also curious to see how this tech gets commercialized in Japan, and if it can bring some relief to those struggling with weight loss. 
$2 billion worth of deals like the one with Takeda could be game changers for SCD's bottom line too.
what's next? cures for every disease